B7-H4-mediated immunoresistance is supressed by PI3K/Akt/mTOR pathway inhibitors
- Autores: Zeng S.1, Song H.1, Chen Y.1, Xie W.2, Zhang L.1
-
Afiliações:
- Department of Biology Pharmaceutics, College of Pharmaceutical Sciences
- Department of Immunology, School of Basic Medicine and Life Sciences
- Edição: Volume 50, Nº 6 (2016)
- Páginas: 887-894
- Seção: Molecular Cell Biology
- URL: https://journal-vniispk.ru/0026-8933/article/view/162891
- DOI: https://doi.org/10.1134/S0026893316060248
- ID: 162891
Citar
Resumo
B7-H4 plays an important role in tumor immune evasion. In previous studies we have found that B7-H4 can translocate to the nucleus, and the exposure to PI3K inhibitor Ly294002 affects B7-H4 subcellular distribution. In this study we report the role of PI3K/Akt pathway in the B7-H4 subcellular distribution and the effect of PI3K/Akt inhibitors on B7-H4-mediated immunoresistance. The involvement of PI3K/Akt pathway in B7-H4 subcellular distribution was evident in experiments with wortmannin, while MDM2 inhibitor nutlin-3 and the mTOR inhibitor rapamycin were used to dissect the signaling downstream of Akt. Wortmannin and rapamycin demonstrated similar effects on B7-H4 subcellular distribution. Exposure to any of these inhibitors decreased levels of membrane B7-H4 while at the same time inducing its nuclear accumulation, while exposure to nutlin-3 had no effect on B7-H4 subcellular distribution. In the T cell proliferation assay, both wortmannin and rapamycin effectively inhibited B7-H4 WT/293 cells-mediated T cell proliferation while exerting no effect on Mock/293 cells. PI3K/Akt/mTOR plays a role in B7-H4 subcellular distribution, while MDM2 does not take part in it. Moreover, we show that wortmannin and rapamycin inhibit B7-H4-mediated tumor immunoresistance through regulating B7-H4 subcellular distribution. Taken together, these results suggest that PI3K/Akt/mTOR inhibitors might be used for adjuvant therapy aimed at inhibition of immune evasion.
Palavras-chave
Sobre autores
S. Zeng
Department of Biology Pharmaceutics, College of Pharmaceutical Sciences
Email: zliang@suda.edu.cn
República Popular da China, Suzhou, 215123
H. Song
Department of Biology Pharmaceutics, College of Pharmaceutical Sciences
Email: zliang@suda.edu.cn
República Popular da China, Suzhou, 215123
Y. Chen
Department of Biology Pharmaceutics, College of Pharmaceutical Sciences
Email: zliang@suda.edu.cn
República Popular da China, Suzhou, 215123
W. Xie
Department of Immunology, School of Basic Medicine and Life Sciences
Email: zliang@suda.edu.cn
República Popular da China, Suzhou, 215123
L. Zhang
Department of Biology Pharmaceutics, College of Pharmaceutical Sciences
Autor responsável pela correspondência
Email: zliang@suda.edu.cn
República Popular da China, Suzhou, 215123
Arquivos suplementares
